Table 2—

Characteristics of the study population at baseline for group I and II

Group IGroup II
Patients1113
Sex
 Male35
 Female88
Age yrs12.5±4.513.5±3.4
FVC % pred81±982±22
FEV1 % pred74±1276±27
MEF25% % pred49±3249±34
Rint,e kPa·L−1·s−10.5±0.210.5±0.23
Use of TSI35
  • Data are presented as n or mean±sd. In the first 2 weeks, group I nebulised recombinant human deoxyribonuclease (rhDNase) before bedtime and placebo in the morning, directly after waking up. In the following 2 weeks the order in which rhDNase and placebo were taken was reversed. Group II nebulised placebo before bedtime and rhDNase after waking up in the first 2 weeks and performed the reverse sequence thereafter. FVC: forced vital capacity; % pred: % predicted; FEV1: forced vital capacity in one second; MEF25%: maximal instantaneous forced flow when 25% of the FVC remained to be exhaled; Rint,e: interrupter resistance exhaled; TSI: tobramycin solution for inhalation.